BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31326556)

  • 21. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers.
    Grandjean M; Sermeus A; Branders S; Defresne F; Dieu M; Dupont P; Raes M; De Ridder M; Feron O
    PLoS One; 2013; 8(10):e76508. PubMed ID: 24130777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma.
    Akhtar J; Priya R; Jain V; Sakhuja P; Agarwal AK; Goyal S; Polisetty RV; Sirdeshmukh R; Kar S; Gautam P
    BMC Cancer; 2020 Dec; 20(1):1175. PubMed ID: 33261560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of RAS mutation by pyrosequencing in thyroid cytology samples.
    Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M
    Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia.
    Izawa S; Okamura T; Matsuzawa K; Ohkura T; Ohkura H; Ishiguro K; Noh JY; Kamijo K; Yoshida A; Shigemasa C; Kato M; Yamamoto K; Taniguchi S
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):35-42. PubMed ID: 23215816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery.
    De Napoli L; Bakkar S; Ambrosini CE; Materazzi G; Proietti A; Macerola E; Basolo F; Miccoli P
    Thyroid; 2016 Mar; 26(3):390-4. PubMed ID: 26548748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
    Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
    Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoseroproteomic profiling in autoantibody to ENO1 as potential biomarker in immunodiagnosis of osteosarcoma by serological proteome analysis (SERPA) approach.
    Li J; Dai L; Huang M; Ma Y; Guo Z; Wang X; Li W; Zhang JY
    Oncoimmunology; 2021; 10(1):1966969. PubMed ID: 38260036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying autoantibody signatures in cancer: a promising challenge.
    Desmetz C; Maudelonde T; Mangé A; Solassol J
    Expert Rev Proteomics; 2009 Aug; 6(4):377-86. PubMed ID: 19681673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum autoantibodies as biomarkers for early cancer detection.
    Tan HT; Low J; Lim SG; Chung MC
    FEBS J; 2009 Dec; 276(23):6880-904. PubMed ID: 19860826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
    Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
    Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
    Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
    Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
    Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.